<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        411-212-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ALVANCO 1000MG POW. FOR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VANCOMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        30.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Sofarimex Ind&#xFA;stria Qu&#xED;mica e Farmac&#xEA;utica, S.A.. " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Sofarimex Indústria Química e Farmacêutica, S.A.. 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A07AA09 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        J01XA01 
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ALVANCO is an antibiotic that belongs to a group of antibiotics called &ldquo;glycopeptides&rdquo;.</p><p>ALVANCO works by eliminating certain bacteria that cause infections.</p><p>ALVANCO powder is made into a solution for infusion or oral solution.</p><p>ALVANCO is used in in all age groups by infusion for the treatment of the following serious infections:</p><p>&bull; Infections of the skin and tissues below the skin.</p><p>&bull; Infections of bone and joints.</p><p>&bull; An infection of the lungs called &quot;pneumonia&quot;.</p><p>&bull; Infection of the inside lining of the heart (endocarditis) and to prevent endocarditis in patients at risk when undergoing major surgical procedures.</p><p>&bull; Infection in central nervous system.</p><p>&bull; Infection in the blood linked to the infections listed above.</p><p>ALVANCO can be given orally in adults and children for the treatment of infection of the mucosa of the small and the large intestines with damage to the mucosae (pseudomembranous colitis), caused by the Clostridium difficile bacterium.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use ALVANCO</strong></p><p>&bull; If you are allergic to vancomycin or any of the other ingredients of this medicine (listed in section 6).</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or hospital pharmacist or nurse before using ALVANCO if:</p><p>&bull; You suffered a previous allergic reaction to teicoplanin because this could mean you are also allergic to vancomycin.</p><p>&bull; You have a hearing disorder, especially if you are elderly (you may need hearing tests during treatment). &bull; You have kidney disorder (you will need to have your blood and kidneys tested during treatment).</p><p>&bull; You are receiving ALVANCO by infusion for the treatment of the diarrhoea associated to Clostridium difficile infection instead of orally.</p><p>Talk to your doctor or hospital pharmacist or nurse during treatment with ALVANCO if:</p><p>&bull; You are receiving ALVANCO for a long time (you may need to have your blood, hepatic and kidneys tested during treatment).</p><p>&bull; You develop any skin reaction during the treatment.</p><p>&bull; You develop severe or prolonged diarrhoea during or after using ALVANCO, consult your doctor immediately. This may be a sign of bowel inflammation (pseudomembranous colitis) which can occur following treatment with antibiotics.</p><p>&nbsp;</p><p><strong>Children</strong></p><p>ALVANCO will be used with particular care in premature infants and young infants, because their kidneys are not fully developed and they may accumulate ALVANCO in the blood. This age group may need blood tests for controlling vancomycin levels in blood. Concomitant administration of ALVANCO and anaesthetic agents has been associated with skin redness (erythema) and allergic reactions in children. Similarly, concomitant use with other medicines such as aminoglycoside antibiotics, nonsteroidal anti-inflammatory agents (NSAIDs, e.g., ibuprofen) or amphotericin B (medicine for fungal infection) can increase the risk of kidney damage and therefore more frequent blood and renal test may be necessary.</p><p><strong>Other medicines and ALVANCO</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken, or might take any other medicines. Moreover, do not take any new medicine without consulting your doctor.</p><p>The following medicines may react with vancomycin if you take them at the same time, such as medicines for the treatment of:</p><p>&bull; infections caused by bacteria (streptomycin, neomycin, gentamicin, kanamycin, amikacin, bacitracin, tobramycin, polymixin B, colistin),</p><p>&bull; tuberculosis (viomycin),</p><p>&bull; fungal infections (amphotericin B),</p><p>&bull; cancer (cisplatin)</p><p>and</p><p>&bull; medicines for muscle relaxation during anaesthesia,</p><p>&bull; anaesthetic agents (if you are going to have general anaesthesia). Your doctor may need to test your blood and adjust the dosage if vancomycin is given simultaneously with other medicines</p><p><strong>Pregnancy</strong></p><p>If you are pregnant, think you may be pregnant or plan to become pregnant, tell your doctor before taking this medicine. ALVANCO should be given during pregnancy and breast-feeding only if clearly needed. Your doctor will decide if you should take ALVANCO.</p><p><strong>Breast-feeding</strong></p><p>Tell your doctor if you are breastfeeding, since ALVANCO passes into breast milk. Your doctor will decide whether vancomycin is really necessary or whether you should stop breastfeeding.</p><p><strong>Driving and using machines</strong></p><p>Vancomycin has no or negligible effect on the ability to drive and use machines.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You will be given ALVANCO by medical staff while you are in hospital. Your doctor will decide how much of this medicine you should receive each day and how long the treatment will last.&nbsp;</p><p><u><strong>Dosage</strong></u></p><p>The dose given to you will depend on:</p><p>&minus; your age,</p><p>&minus; your weight,</p><p>&minus; the infection you have,</p><p>&minus; how well your kidneys are working,</p><p>&minus; your hearing ability,</p><p>&minus; any other medicines you may be taking.&nbsp;</p><p><u><strong>Intravenous administration </strong></u></p><p><strong>Adults and adolescents (from 12 years and older) </strong></p><p>The dosage will be calculated according to your body weight. The usual infusion dose is 15 to 20 mg for each kg of body weight. It is usually given every 8 to 12 hours. In some cases, your doctor may decide to give an initial dose of up to 30 mg for each kg of body weight. The maximum daily dose should not exceed 2 g</p><p><strong>Use in children </strong></p><p><u>Children aged from one month to less than 12 years of age</u></p><p>The dosage will be calculated according to your body weight. The usual infusion dose is 10 to 15 mg for each kg of body weight. It is usually given every 6 hours.</p><p><u>Preterm and term newborn infants (from 0 to 27 days)</u></p><p>The dosage will be calculated according to post-menstrual age (time elapsed between the first day of the last menstrual period and birth (gestational age) plus the time elapsed after birth (postnatal age). The elderly, pregnant women and patients with a kidney disorder, including those on dialysis, may need a different dose.</p><p><u><strong>Oral administration </strong></u></p><p><strong>Adults and adolescents (from 12 to 18 years)</strong></p><p>The recommended dose is 125 mg every 6 hours. In some cases, your doctor may decide to give a higher daily dose of up to 500 mg every 6 hours. The maximum daily dose should not exceed 2 g. If you suffered other episodes (infection of the mucosa) before you may need different dose and different duration of the therapy.</p><p><strong>Use in children</strong></p><p><strong>Neonates, infants and children less than 12 years old </strong></p><p>The recommended dose is 10 mg for each kg of body weight. It is usually given every 6 hours. The maximum daily dose should not exceed 2 g.</p><p><u><strong>Method of administration </strong></u></p><p>Intravenous infusion means that the medicinal product flows from an infusion bottle or bag through a tube to one of your blood vessels and into your body. Your doctor, or nurse, will always give ALVANCO into your blood and not in the muscle. ALVANCO will be given into your vein for at least 60 minutes. If given for treatment of gastric disorders (so called Pseudomembranous colitis), the medicinal product must be administrated as a solution for oral use (you will take the medicine by mouth).</p><p><strong>Duration of treatment</strong></p><p>The length of treatment depends on the infection you have and may last a number of weeks. The duration of the therapy may be different depending on the individual response to treatment for every patient. During the treatment, you might have blood tests, be asked to provide urine samples and possibly have hearing tests to look for signs of possible side effects.</p><p><strong>If you receive more Vancomycin than you should</strong></p><p>As this product will be given to you while you are in the hospital, it is unlikely that you will be given too much. However, tell your doctor or nurse immediately if you have any concerns. If you have further questions about using this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ALVANCO can cause allergic reactions, although serious allergic reactions (anaphylactic shock) are rare. Tell your doctor immediately if you get any sudden wheeziness, difficulty in breathing, redness on the upper part of the body, rash or itching.</p><p>The absorption of ALVANCO from the gastrointestinal tract is negligible. However, if you have an inflammatory disorder of the digestive tract, especially if you also have a kidney disorder, side effects that occur when ALVANCO is administered by infusion may appear.</p><p><strong>Common side effects (may affect up to 1 in 10 people):</strong></p><p>&minus; Fall in blood pressure.</p><p>&minus; Breathlessness, noisy breathing (a high pitched sound resulting from obstructed air flow in the upper airway).</p><p>&minus; Rash and inflammation of the lining of the mouth, itching, itching rash, hives.</p><p>&minus; Kidney problems which may be detected primarily by blood tests.</p><p>&minus; Redness of upper body and face, inflammation of a vein.</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people): </strong></p><p>- Temporary or permanent loss of hearing</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people):</strong></p><p>- Decrease in white blood cells, red blood cells and platelets (blood cells responsible for blood clotting).</p><p>- Increase in some of the white cells in the blood.</p><p>- Loss of balance, ringing in your ears, dizziness.</p><p>- Blood vessel inflammation.</p><p>&nbsp;- Nausea (feeling sick).</p><p>- Inflammation of the kidneys and kidney failure.</p><p>- Pain in the chest and back muscles.</p><p>- Fever, chills.</p><p><strong>Very rare side effects (may affect up to 1 in 10,000 people):</strong></p><p>- Sudden onset of severe allergic skin reaction with skin flaking blistering or peeling skin. This may be associated with a high fever and joint pains.</p><p>- Cardiac arrest</p><p>- Inflammation of the bowel which causes abdominal pain and diarrhea, which may contain blood.</p><p><strong>Not known (frequency cannot be estimated from the available data): </strong></p><p>- Being sick (throwing up), diarrhea.</p><p>- Confusion, drowsiness, lack of energy, swelling, fluid retention, decreased urine.</p><p>- Rash with swelling or pain behind the ears, in the neck, groin, under the chin and armpits (swollen lymph nodes), abnormal blood and liver function tests.</p><p>- Rash with blisters and fever.&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance and Drug Safety Centre (NPC). By reporting side affects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Before reconstitution: Do not store above 30&deg; C.</p><p>&bull; Keep the vial in the outer carton in order to protect from light.</p><p>&bull; Keep out of the reach and sight of children.</p><p>&bull; Do not use this medicine after the expiry date printed on the label and carton. The expiry date refers to the last day of that month.</p><p>&bull; Do not use this medicine if you notice that the solution is cloudy or there are particles in suspension.</p><p>&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is vancomycin (as hydrochloride).</p><p>ALVANCO 500 mg: Each vial contains 500 mg of vancomycin hydrochloride equivalent to 500 000 IU vancomycin.</p><p>ALVANCO 1000 mg: Each vial contains 1000 mg of vancomycin hydrochloride equivalent to 1 000 000 IU vancomycin.</p><p>The other ingredients are sodium hydroxide, hydrochloric acid for pH adjustment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ALVANCO 500 mg comes in the form of powder, white or slightly brownish, in vials of clear
glass with rubber stopper and orange aluminium cap.
ALVANCO 1000 mg comes in the form of powder, white or slightly brownish, in vials of clear
glass with rubber stopper and white aluminium cap.

Each package can contain 1, 5, 10 or 20 vials.
Before use, the powder is dissolved and diluted with an intravenous liquid, obtaining a solution
which will be administered to you slowly into the vein, by drip, by a doctor or nurse.

ALVANCO 500 mg:
Each vial contains 500 mg of vancomycin hydrochloride. After reconstitution with 10 ml of
water for injections, it is obtained a solution with a concentration of 50 mg/ml, and after further
dilutions a solution with concentration of 5 mg/ml is obtained.

ALVANCO 1000 mg:
Each vial contains 1000 mg of vancomycin hydrochloride. After reconstitution with 20 ml of
water for injections, it is obtained a solution with a concentration of 50 mg/ml, and after further
dilutions a solution with concentration of 5 mg/ml is obtained.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufactured by:</p><p>Sofarimex &ndash; Ind&uacute;stria Qu&iacute;mica e Farmac&ecirc;utica, S.A.</p><p>Av. das Ind&uacute;stria, Alto de Colaride</p><p>2735-213 Cac&eacute;m</p><p>Portugal</p><p>For: SPIMACO</p><p>Al-Qassim pharmaceutical plant</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>الڤانكو هو مضاد حيوي ينتمي إلى مجموعة من المضادات الحيوية التي تسمى &quot;جليكوبيبتيديز&quot;. ويعمل الڤانكو بالقضاء على بعض البكتيريا التي تسبب العدوى. مسحوق الڤانكو محضر في محلول للحقن الوريدي أو عن طريق الفم. الڤانكو يستخدم في جميع الفئات العمرية بالحقن الوريدي لعلاج الإصابات الخطيرة التالية:</p><p>&minus; التهابات الجلد والأنسجة تحت الجلد.</p><p>&minus; التهابات العظام والمفاصل.</p><p>&minus; التهاب في الرئتين يسمى &quot;الالتهاب الرئوي&quot;.&nbsp;</p><p>&minus; عدوى البطانة الداخلية للقلب (التهاب الشغاف) ومنع التهاب بطانة القلب في المرضى المعرضين للخطر عندما يخضعون لعمليات جراحية كبيرة</p><p>&minus; الإصابة في الجھاز العصبي المركزي.</p><p>&minus; عدوي الدم المرتبطة بالأمراض المذكورة أعلاه.</p><p>يمكن أن يعطي الڤانكو عن طريق الفم في البالغين والأطفال لعلاج التهاب الغشاء المخاطي في الأمعاء الدقيقة و الغليظة مع الإضرار بالغشاء المخاطي (التهاب القولون الغشائي)، الناجمة عن بكتيريا المطثية العسيرة .&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; إذا كانت لديك حساسية من ڤانكومايسين أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6)</p><p><strong>التحذيرات والاحتياطات </strong></p><p>تحدث إلى طبيبك أو صيدلي المستشفى أو الممرضة قبل استخدام الڤانكو إذا :</p><p>&minus; عانيت مسبقا لرد فعل تحسسي من تيكوبلانين لأن هذا من الممكن أن يعني أن لديك حساسية أيضا من ڤانكومايسين.</p><p>&minus; كان لديك اضطراب في السمع، خاصة إذا كنت من كبار السن (قد تحتاج اجراء اختبارات للسمع أثناء فترة العلاج).</p><p>&minus; كانت لديك اضطرابات في الكلي (قد تحتاج إلى اجراء اختبارات للدم والكليتين أثناء العلاج).&nbsp;</p><p>&minus; كنت تتلقى الڤانكو عن طريق الحقن الوريدي لعلاج الإسهال المرتبط بعدوى بكتيريا المطثية العسيرة بدلا تناوله عن طريق الفم.</p><p>تحدث إلى طبيبك أو صيدلي المستشفي أو الممرضة أثناء العلاج باستخدام الڤانكو إذا:</p><p>&minus; كنت تتلقى الڤانكو لفترة طويلة (قد تحتاج اجراء اختبارت للدم، والكبد والكليتين أثناء فترة العلاج الخاصة بك).</p><p>&minus; ظهر أي رد فعل تحسسي على الجلد أثناء فترة العلاج.</p><p>&minus; أصبت بإسهال حاد أو لفترات طويلة أثناء أو بعد استخدام الڤانكو، استشر طبيبك فورا. قد يكون هذا علامة على التهاب الأمعاء (التهاب القولون الغشائي الكاذب) الذي يمكن أن يظهر بعد العلاج بالمضادات الحيوية.&nbsp;</p><p>&nbsp;</p><p><strong>الأطفال</strong></p><p>يستخدم الڤانكو بعناية خاصة في الخدج والرضع الصغار، لأن كليتهم ليست مكتملة النضوج، مما قد يتسبب في تراكم الڤانكو في الدم. قد تحتاج هذه الفئة العمرية إلى اختبارات الدم للسيطرة على مستويات الڤانكوميسين في الدم.</p><p>تناول الڤانكو بالتزامن مع عوامل التخدير قد يصاحبه احمرار الجلد (الحمامي) والحساسية لدى الأطفال. وبالمثل، ما يصاحب استخدامه بالتزامن مع الأدوية الأخرى مثل المضادات الحيوية امينوجليكوزيد، ومضادات الالتهاب اللاستيرويدية (المسكنات، مثل آيبوبروفين) أو الامفوتريسين ب (دواء للعدوى الفطرية) يمكن أن يزيد من خطر الضرر الكلوي، وبالتالي اختبارات الدم والكلى المتكررة قد تكون ضرورية.</p><p><strong>الادوية الاخرى والڤانكو</strong></p><p>أخبر طبيبك أو الصيدلي أو الممرضة إذا كنت تتناول أو تناولت مؤخرا، أو قد تتناول أي أدوية أخرى .علاوة على ذلك،لا&nbsp;تتناول أي دواء جديد دون استشارة طبيبك.</p><p>قد تتفاعل الادوية التالية مع ڤانكومايسين إذا كنت تتناولها في نفس الوقت، مثل الادوية التي تستخدم لعلاج:</p><p>&bull; العدوى التي تسببها البكتيريا (ستربتومايسين ، نيومايسين ، جنتاميسين ، كانامايسين ، أميكاسين ، باكيتراسين ، توبراميسين ، بوليميكسين ب ، كوليستين)</p><p>&bull; مرض السل(فيوميسين)</p><p>&bull; الالتهابات الفطرية(الامفوتريسين ب)</p><p>&bull; السرطان (سيسبلاتين)&nbsp;</p><p>&bull; الادوية المستخدمة لاسترخاء العضلات أثناء التخدير،</p><p>&bull; مواد التخدير (إذا كنت ستخضع للتخدير الكلي).</p><p>قد يحتاج طبيبك إلى اجراء اختبارات الدم لديك وضبط الجرعة إذا تم إعطاء الڤانكومايسين في وقت واحد مع أدوية أخرى</p><p><strong>الحمل&nbsp;</strong></p><p>إذا كنتي حاملا ,&nbsp; أو تعتقدين أنك حاملا&nbsp;أو تخططين للحمل، أخبري طبيبك قبل تناول هذا الدواء. يجب إعطاء الڤانكو أثناء الحمل والرضاعة الطبيعية فقط إذا لزم األمر. سوف يقرر طبيبك إذا كان يجب عليكي أن تتلقى هذا الدواء.</p><p><strong>الرضاعة الطبيعية</strong></p><p>أخبري طبيبك إذا كنت ترضعين طفلك رضاعة طبيعية، لان الڤانكو ينتقل إلى حليب الام. سيقرر طبيبك ما إذا كان&nbsp;الڤانكومايسين&nbsp;ضروريًا حقًا&nbsp;أم يجب عليك التوقف عن الرضاعة الطبيعية</p><p><strong>القيادة واستخدام الآلات</strong></p><p>الڤانكو ليس له أي تأثير على القدرة على القيادة واستخدام الالات</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سوف تتلقي الڤانكو من الطاقم الطبي أثناء وجودك في المستشفى. سوف يقرر طبيبك كمية الدواء التي يجب أن تتلقاها كل يوم، وكم من الوقت سوف تستمر فترة العلاج.&nbsp;</p><p><u><strong>الجرعة</strong></u></p><p>الجرعة المعطاة لك تعتمد على:</p><p>&minus; عمرك،</p><p>&minus; الوزن الخاص بك،</p><p>&minus; العدوى المصاب بها،</p><p>&minus; كفاءة عمل الكليتين،</p><p>&minus; قدرتك على السمع،</p><p>&minus; أي أدوية أخرى قد تكون تتناولها</p><p><u><strong>تناول الدواء عن طريق الحقن الوريدي </strong></u></p><p><strong>البالغين والمراهقين (من 12 سنة وكبار السن)&nbsp;</strong></p><p>سوف تحسب الجرعة وفقا لوزن الجسم. الجرعة المعتادة للتسريب الوريدي هي من 15 إلى 20 ملجم لكل كجم من وزن الجسم. عادة ما يعطي كل 8 إلى 12 ساعة. وفي بعض الحالات، قد يقرر الطبيب إعطاء جرعة أولية تصل إلى 30 ملجم لكل كجم من وزن الجسم. ويجب أن لا تتجاوز الجرعة اليومية القصوى 2 جم.</p><p>&nbsp;</p><p><strong>الاستخدام في الأطفال</strong></p><p><u>الأطفال الذين تتراوح أعمارهم بين شهر واحد إلى أقل من 12 سنة</u></p><p>سوف تحسب الجرعة وفقا لوزن الجسم. الجرعة المعتادة للتسريب الوريدي هي من 10 إلى 15 ملجم لكل كجم من وزن الجسم. عادة ما تعطي كل 6 ساعات.</p><p><u>الأطفال الرضع حديثي الولادة الخدج ومكتملي النمو (من 0 إلى 27 یوما) </u></p><p>سوف تحسب الجرعة حسب العمر بعد انتهاء الحيض (الوقت المنقضي بين اليوم الأول من فترة الحيض الماضي والولادة (العمر الحملي) بالإضافة إلى الوقت المنقضي بعد الولادة (عمر ما بعد الولادة).</p><p>النساء المسنات، والنساء الحوامل والمرضى الذين يعانون من اضطراب في الكلى، بما في ذلك المرضى الخاضعين للغسيل الكلوي، قد يحتاجوا إلى جرعة مختلفة.&nbsp;</p><p>&nbsp;</p><p><strong><u>تناول الدواء عن طريق الفم </u></strong></p><p><strong><u>البالغين والمراهقين (من 12 إلى 18 سنة)&nbsp;</u></strong></p><p>الجرعة الموصى بها هي 125 ملجم كل 6 ساعات. وفي بعض الحالات، قد يقرر الطبيب إعطاء جرعة يومية أعلى تصل إلى 500 ملجم كل 6 ساعات. وينبغي أن لا تتجاوز الجرعة اليومية القصوى 2 جم.</p><p>إذا تعرضت من قبل لحالات أخرى (التهاب الغشاء المخاطي) قد تحتاج جرعة مختلفة وفترة مختلفة للعلاج.&nbsp;</p><p><strong>الاستخدام في الأطفال</strong></p><p><u>حديثي الولادة والرضع والأطفال أقل من 12 سنة </u></p><p>الجرعة الموصى بها 10 ملجم لكل كجم من وزن الجسم. عادة ما تعطي كل 6 ساعات. وينبغي أن لا تتجاوز الجرعة اليومية القصوى 2 جم.&nbsp;</p><p>&nbsp;</p><p><strong><u>طريقة الإعطاء </u></strong></p><p>التسريب الوريدي يعني تدفق المنتجات الطبية من زجاجة أو عبوة الحقن الوريدي من خلال أنبوب إلى واحدة من الأوعية الدموية الخاصة بك ومن ثم إلي جسمك. سوف يقوم طبيبك، أو الممرضة، دائما بإعطائك الڤانكو في الدم وليس في العضلات.</p><p>سوف يعطي الڤانكو في وريدك لمدة 60 دقيقة على الأقل.</p><p>إذا تم إعطاؤه لعلاج اضطرابات المعدة (ما يسمى التهاب القولون الغشائي الكاذب)، يجب أن يعطي المنتج الطبي كمحلول للاستخدام عن طريق الفم (سوف تتناول الدواء عن طريق الفم).</p><p><strong>فترة العلاج</strong></p><p>مدة العلاج تعتمد على العدوى لديك وقد تستمر لعدة أسابيع.</p><p>مدة العلاج قد تكون مختلفة اعتمادا على الاستجابة الفردية للعلاج لكل مريض</p><p>خلال العلاج، قد تقوم باختبارات الدم، يطلب منك توفير عينات بول وربما تقوم باختبارات السمع للبحث عن علامات أعراض جانبية محتملة</p><p>&nbsp;</p><p><strong>إذا تلقيت الڤانكو أكثر مما يجب</strong></p><p>ليس من المرجح أن تحصل على جرعة زائدة لان هذا المنتج سيتم إعطاؤه لك أثناء تواجدك في المستشفى، إذا كانت لديك أي مخاوف أخبر طبيبك أو الممرضة على الفور.</p><p>إذا كانت لديك أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي أو الممرضة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>الڤانكو يمكن أن يسبب الحساسية، على الرغم من أن الحساسية الخطيرة (صدمة تاقية)&nbsp; نادرة. </strong></p><p><strong>أخبر طبيبك فورا إذا تعرضت إلى أي تنفس بصفير بشكل مفاجئ، صعوبة في التنفس، واحمرار في الجزء العلوي من الجسم، والطفح الجلدي أو الحكة.</strong></p><p>يمتص الڤانكو من الجهاز الهضمي بشكل لا&nbsp;يذكر. ومع ذلك، إذا كان لديك اضطراب التهابي في الجهاز الهضمي، خاصة إذا كان لديك أيضا اضطراب في الكلى، قد تظهر عليك الاعراض الجانبية التي تظهر عند اعطاء الڤانكو في صورة التسريب الوريدي.</p><p>&nbsp;</p><p><strong>أعراض جانبية شائعة (قد تؤثر على&nbsp;ما يصل إلى 1 في 10 أشخاص)</strong>:</p><p>&minus; انخفاض في ضغط الدم.</p><p>&minus; ضيق التنفس، التنفس بصوت صاخب (صوت عالي النبرة ناجم عن إعاقة تدفق الهواء في مجرى الهواء العلوي).&nbsp;</p><p>&minus; طفح جلدي والتهاب بطانة الفم، حكة، طفح جلدي، الشري.</p><p>&minus; مشاكل في الكلى والتي يمكن الكشف عنها مبدئيا بواسطة اختبارات الدم.</p><p>&minus; احمرار في الجزء العلوي من الجسم والوجه، والتهاب الوريد.</p><p><strong>أعراض جانبية غير شائعة (قد تؤثر على&nbsp;ما يصل إلى 1 في 100 شخص):</strong></p><p>&minus; فقدان السمع المؤقت أو الدائم.&nbsp;</p><p><strong>أعراض جانبية نادرة (قد تؤثر على&nbsp;ما يصل إلى 1 في 1000 شخص):</strong></p><p>&minus; انخفاض في خلايا الدم البيضاء، وخلايا الدم الحمراء والصفائح الدموية (خلايا الدم المسؤولة عن تخثر الدم).</p><p>&minus; زيادة في بعض الخلايا البيضاء في الدم.</p><p>&minus; فقدان التوازن، ورنين في اذنيك، الدوخة.</p><p>&minus; التهاب الأوعية الدموية.</p><p>&minus; غثيان (الشعور بالإعياء).</p><p>&minus; التهاب الكلى والفشل الكلوي.</p><p>&minus; ألم في عضلات الصدر والظهر</p><p>&nbsp;&minus; حمى، قشعريرة.&nbsp;</p><p><strong>أعراض جانبية نادرة جدا ( قد تؤثر على ما يصل إلى 1 في 10000 شخص):&nbsp;</strong></p><p>&minus; رد فعل تحسسي شديد على الجلد بشكل مفاجئ مع تساقط بثور على الجلد أو تقشير الجلد. وهذا قد يصاحبه ارتفاع في درجة الحرارة وآلام المفاصل.</p><p>&minus; سكتة قلبية.</p><p>&minus; التهاب الأمعاء الذي يسبب آلام البطن والإسهال، الذي قد يحتوي على دم.&nbsp;</p><p><strong>غير معروف (لا يمكن تقدير معدل تكرار حدوثها من المعلومات المتوفرة):</strong></p><p>&minus; الشعور بالإعياء (القئ)، والإسهال.</p><p>&minus; الارتباك، النعاس، والافتقار إلى الطاقة، وتورم، احتباس السوائل، انخفاض البول.</p><p>&minus; طفح جلدي مع تورم أو ألم خلف الأذنين، والرقبة، الفخذ، تحت الذقن والإبطين (تضخم الغدد الليمفاوية) واختبارات الدم ووظائف الكبد تظهر بصورة غير طبيعية.</p><p>&minus; طفح جلدي مع بثور وحمى.</p><p><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p>اذا ظهرت عليك أي أعراض جانبية، قم بالتحدث مع طبيبك أو الصيدلي أو الممرضة. ويشمل ذلك أي أعراض جانبية محتملة غير المدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الأعراض الجانبية مباشرة عبر المركز الوطني للتيقظ و السلامة الدوائية. يمكنك من خلال الإبلاغ عن الأعراض الجانبية أن تساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>قبل تكوين المحلول: لا يحفظ في درجة حرارة أعلى من 30 درجة مئوية.</li><li>إبقاء القارورة في الكارتون الخارجي من أجل الحماية من الضوء.</li><li>يحفظ بعيدا عن متناول ونظر الأطفال.</li><li>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المطبوع على الملصق والكرتون.يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</li><li>لا تستخدم هذا الدواء إذا لاحظت أن المحلول غائم أو أن هناك جسيمات في المعلق.</li><li>لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ومن شأن هذه التدابير أن تساعد على حماية البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&minus; المادة الفعالة هي ڤانكومايسين (على هيئة هيدروكلوريد).</p><p>الڤانكو 500 ملجم : كل قارورة تحتوي على 500 ملجم من ڤانكومايسين&nbsp;هيدروكلوريد يعادل ما لا يقل عن 500000 وحدة دولية.</p><p>الڤانكو 1000 ملجم : كل قارورة تحتوي على 1000 ملجم من ڤانكومايسين&nbsp;هيدروكلوريد يعادل ما لا يقل عن1000000 وحدة دولية.&nbsp;</p><p>المكونات الأخرى هي هيدروكسيد الصوديوم، حمض الهيدروكلوريك لتعديل الرقم الهيدروجيني.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>الڤانكو 500 ملجم يأتي في شكل مسحوق، أبيض أو بني قليلا، في قارورة من الزجاج الشفاف مع سدادة مطاطية وغطاء الألومنيوم البرتقالي</p><p>الڤانكو 1000 ملجم يأتي في شكل مسحوق، أبيض أو بني قليلا، في قارورة من الزجاج الشفاف مع سدادة مطاطية وغطاء الألومنيوم الأبيض.</p><p>كل عبوة يمكن أن تحتوي على 1 ،5 ،10 أو 20 قارورة.</p><p>قبل الاستخدام، يذاب المسحوق ويخفف مع سائل وريدي، للحصول على المحلول الذي سوف يتم إعطاؤه لك ببطء في الوريد، بالتنقيط، من قبل طبيب أو ممرضة.</p><p>الڤانكو 500 ملجم:</p><p>كل قارورة تحتوي على 500 ملجم من ڤانكومايسين هيدروكلوريد. بعد تحليل المسحوق مع 10 مل من الماء للحقن، يتم الحصول على محلول تركيزه 50 ملجم/ مل، وبعد مزيد من التخفيفات يتم الحصول على محلول تركيزه 5 ملجم / مل</p><p>الڤانكو 1000 ملجم:</p><p>كل قارورة تحتوي على 1000 ملجم من ڤانكومايسين هيدروكلوريد. بعد تحليل المسحوق مع 20 مل من الماء للحقن، يتم الحصول على محلول تركيزه 50 ملجم / مل، وبعد مزيد من التخفيفات يتم الحصول على محلول تركيزه 5 ملجم / مل.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>المصنع</strong></p><p>سوفاريمكس- للصناعات الكيميائية والصيدلانية، إس.إيه.</p><p>شارع داس إندوستريا ، ألتو دي كوالريد</p><p>2735-213 كاسيم</p><p>البرتغال</p><p><strong>لصالح</strong></p><p><strong>الدوائية</strong></p><p>مصنع الادوية بالقصيم</p><p>المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alvanco 1000 mg, Powder for concentrate for solution for infusion

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alvanco 1000 mg, Powder for concentrate for solution for infusion
Each vial contains 1000 mg of vancomycin (as vancomycin hydrochloride), equivalent to 
1,000,000 IU vancomycin.
One ml of reconstituted solution contains 50 mg of vancomycin.
For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion.
Homogeneous solid, white to slightly brown.
After reconstitution a solution is obtained with a pH between 2.5 – 4.5.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Intravenous administration</u></p><p>Alvanco is indicated in all age groups for the treatment of the following infections (see sections 4.2, 4.4 and 5.1):</p><p>&bull; complicated skin and soft tissue infections (cSSTI)</p><p>&bull; bone and joint infections</p><p>&bull; community acquired pneumonia (CAP)</p><p>&bull; hospital acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP)</p><p>&bull; infective endocarditis</p><p>&bull; bacteraemia that occurs in association with, or is suspected to be associated with any of the above.</p><p>Alvanco is also indicated in all age groups for the perioperative antibacterial prophylaxis in patients that are at high risk of developing bacterial endocarditis when undergoing major surgical procedures.</p><p><u>Oral administration </u></p><p>Alvanco is indicated in all age groups for the treatment of Clostridium difficile infection (CDI) (see sections 4.2, 4.4 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology </u></p><p>Where appropriate, ALVANCO should be administered in combination with other antibacterial agents.</p><p><em>Intravenous administration</em></p><p>The initial dose should be based on total body weight. Subsequent dose adjustments should be based on serum concentrations to achieve targeted therapeutic concentrations. Renal function must be taken into consideration for subsequent doses and interval of administration.</p><p><u><em>Patients aged 12 years and older </em></u></p><p>The recommended dose is 15 to 20 mg/kg of body weight every 8 to 12 h (not to exceed 2 g per dose). In seriously ill patients, a loading dose of 25&ndash;30 mg/kg of body weight can be used to facilitate rapid attainment of target trough serum vancomycin concentration.</p><p><u><em>Infants and children aged from one month to less than 12 years of age: </em></u></p><p>The recommended dose is 10 to 15 mg/kg body weight every 6 hours (see section 4.4).</p><p><u><em>Term neonates (from birth to 27 days of post-natal age) and preterm neonates (from birth to the expected date of delivery plus 27 days)</em></u></p><p>For establishing the dosing regimen for neonates, the advice of a physician experienced in the management of neonates should be sought. One possible way of dosing vancomycin in neonates is illustrated in the following table: (see section 4.4)</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>PMA (weeks)</td><td>Dose (mg/kg)</td><td>Interval of administration (h)</td></tr><tr><td>&lt;29</td><td>15</td><td>24</td></tr><tr><td>29-35</td><td>15</td><td>12</td></tr><tr><td>&gt;35</td><td>15</td><td>8</td></tr></tbody></table><p>PMA: post-menstrual age [(time elapsed between the first day of the last menstrual period and birth (gestational age) plus the time elapsed after birth (post-natal age)].</p><p>Peri-operative prophylaxis of bacterial endocarditis in all age groups The recommended dose is an initial dose of 15 mg/kg prior to induction of anaesthesia. Depending on the duration of surgery, a second vancomycin dose may be required.</p><p>Duration of treatment Suggested treatment duration is shown in table below. In any case, the duration of treatment should be tailored to the type and severity of infection and the individual clinical response.</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>Indication</td><td>Treatment Duration</td></tr><tr><td><p>Complicated skin and soft tissue infections</p><p>-Non necrotizing</p><p>-Necrotizing</p></td><td><p>7 to 14 days</p><p>4 to 6 weeks*</p></td></tr><tr><td>Bone and joint infections</td><td>4 to 6 weeks**</td></tr><tr><td>Community-aquired pneumonia</td><td>7 to 14 days</td></tr><tr><td>Hospital acquired pneumonia, including ventilatorassociated pneumonia</td><td>7 to 14 days</td></tr><tr><td>Infective endocarditis</td><td>4 to 6 weeks***</td></tr></tbody></table><p>*Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours</p><p>**Longer courses of oral suppression treatment should be considered for prosthetic joint infections</p><p>***Duration and need for combination therapy is based on valve-type and organism</p><p><u>Special populations</u></p><p><em>Elderly </em></p><p>Lower maintenance doses may be required due to the age-related reduction in renal function.</p><p>Renal impairment</p><p>In adult and paediatric patients with renal impairment, consideration should be given to an initial starting dose followed by serum vancomycin trough levels rather than to a scheduled dosing regimen, particularly in patients with severe renal impairment or those who undergo renal replacement therapy (RRT) due to the many varying factors that may affect vancomycin levels in them. In patients with mild or moderate renal failure, the starting dose must not be reduced. In patients with severe renal failure, it is preferable to prolong the interval of administration rather than administer lower daily doses. Appropriate consideration should be given to the concomitant administration of medicinal products that may reduce vancomycin clearance and/or potentiate its undesirable effects (see section 4.4). Vancomycin is poorly dialyzable by intermittent hemodialysis. However, use of high-flux membranes and continuous renal replacement therapy (CRRT) increases vancomycin clearance and generally requires replacement dosing (usually after the haemodialysis session in case of intermittent haemodialysis).</p><p>Adults</p><p>Dose adjustments in adult patients could be based on glomerular filtration rate estimated (eGFR) by the following formula:</p><p>Men: [Weight (kg) x 140 - age (years)]/ 72 x serum creatinine (mg/dl)</p><p>Women: 0.85 x value calculated by the above formula.</p><p>The usual starting dose for adult patients is 15 to 20 mg/kg that could be administered every 24 hours in patients with creatinine clearance between 20 to 49 ml/min. In patients with severe renal impairment (creatinine clearance below 20 ml/min) or those on renal replacement therapy, the appropriate timing and amount of subsequent doses largely depend on the modality of RRT and should be based on serum vancomycin trough levels and on residual renal function (see section 4.4). Depending on the clinical situation, consideration could be given to withhold the next dose while awaiting the results of vancomycin levels. In the critically ill patient with renal insufficiency, the initial loading dose (25 to 30 mg/kg) should not be reduced.</p><p><u>Paediatric population</u></p><p>Dose adjustments in paediatric patients aged 1 year and older could be based on glomerular filtration rate estimated (eGFR) by the revised Schwartz formula:</p><p>eGFR (mL/min/1.73m2 ) = (height cm x 0.413)/ serum creatinine (mg/dl)</p><p>eGFR (mL/min/1.73m2 ) = (height cm x 36.2/serum creatinine (&mu;mol/L)</p><p>For neonates and infants below 1 year of age, expert advice should be sought as the revised Schwartz formula is not applicable to them.</p><p>Orientative dosing recommendations for the paediatric population are shown in table below that follow the same principles as in adult patients.</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>GFR (mL/min/1.73 m2 )</td><td>IV dose</td><td>Frequency</td></tr><tr><td>50-30</td><td>15 mg/kg</td><td>12 hourly</td></tr><tr><td>29-10</td><td>15 mg/kg</td><td>24 hourly</td></tr><tr><td>&lt; 10&nbsp;</td><td rowspan="3" colspan="1">10-15 mg/kg</td><td rowspan="3" colspan="1">Re-dose based on levels*</td></tr><tr><td>Intermittent haemodialysis</td></tr><tr><td>Peritoneal dialysis</td></tr><tr><td>Continuous renal replacement therapy</td><td>15 mg/kg</td><td>Re-dose based on levels*</td></tr></tbody></table><p>*The appropriate timing and amount of subsequent doses largely depends on the modality of RRT and should be based on serum vancomycin levels obtained prior to dosing and on residual renal function. Depending on the clinical situation, consideration could be given to withhold the next dose while awaiting the results of vancomycin levels.</p><p><u>Hepatic impairment: </u></p><p>No dose adjustment is needed in patients with hepatic insufficiency.</p><p><u>Pregnancy</u></p><p>Significantly increased doses may be required to achieve therapeutic serum concentrations in pregnant women (see Section 4.6).</p><p><u>Obese patients</u></p><p>In obese patients, the initial dose should be individually adapted according to total body weight as in non-obese patients.</p><p><u>Oral Administration</u></p><p>Patients aged 12 years and older</p><p>Treatment of Clostridium difficile infection (CDI):</p><p>The recommended vancomycin dose is 125 mg every 6 hours for 10 days for the first episode of nonsevere CDI. This dose can be increased to 500 mg every 6 hours for 10 days in case of severe or complicated disease. The maximum daily dose should not exceed 2 g.</p><p>In patients with multiple recurrences, consideration may be given to treat the current episode of CDI with vancomycin, 125 mg four times daily for 10 days followed by either tapering the dose, i.e., gradually decreasing it until 125 mg per day or a pulse regimen, i.e., 125&ndash;500 mg/day every 2&ndash;3 days for at least 3 weeks.</p><p>Neonates, infants and children less than 12 years old</p><p>The recommended vancomycin dose is 10 mg/kg orally every 6 hours for 10 days. The maximum daily dose should not exceed 2 g. Treatment duration with vancomycin may need to be tailored to the clinical course of individual patients. Whenever possible the antibacterial suspected to have caused CDI should be discontinued. Adequate replacement of fluid and electrolytes should be ensured</p><p><u>Monitoring of vancomycin serum concentrations </u></p><p>The frequency of therapeutic drug monitoring (TDM) needs to be individualized based on the clinical situation and response to treatment, ranging from daily sampling that may be required in some hemodynamically unstable patients to at least once weekly in stable patients showing a treatment response. In patients with normal renal function, the serum concentration of vancomycin should be monitored on the second day of treatment immediately prior to the next dose. In patients on intermittent haemodialysis, vancomycin levels should be usually obtained before the start of the haemodialysis session. After oral administration, monitoring vancomycin serum concentrations in patients with inflammatory intestinal disorders should be performed (see section 4.4). Therapeutic trough (minimum) vancomycin blood levels should normally be 10-20 mg/l, depending on the site of infection and susceptibility of the pathogen. Trough values of 15-20 mg/l are usually recommended by clinical laboratories to better cover susceptible pathogens with MIC &ge;1 mg/L (see sections 4.4 and 5.1). Model-based methods may be useful in the prediction of individual dose requirements to reach an adequate AUC. The model-based approach can be used both in calculating the personalized starting dose and for dose adjustments based on TDM results (see section 5.1)</p><p><u><em>Method of administration</em></u></p><p><u><em>Intravenous administration</em></u></p><p>Intravenous vancomycin is usually administered as an intermittent infusion and the dosing recommendations presented in this section for the intravenous route correspond to this type of administration. Vancomycin shall only be administered as slow intravenous infusion of at least one hour duration or at a maximum rate of 10 mg/min (whichever is longer) which is sufficiently diluted (at least 100 ml per 500 mg or at least 200 ml per 1000 mg) (see section 4.4).</p><p>Patients whose fluid intake must be limited can also receive a solution of 500 mg/50 ml or 1000 mg/100 ml, although the risk of infusion-related undesirable effects can be increased with these higher concentrations.</p><p>For information about the preparation of the solution, please see section 6.6. Continuous vancomycin infusion may be considered, e.g., in patients with unstable vancomycin clearance.</p><p><em><u>Oral administration</u></em></p><p>For oral use after dissolution. The content of one vial should be given to the patient to drink in part quantities or through a stomach tube. Information on reconstitution and dilution of the medicinal product before use, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see section 4.4).
ALVANCO should not be administered intramuscularly due to the risk of necrosis at the site of
administration
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity reactions</u></p><p>Serious and occasionally fatal hypersensitivity reactions are possible (see sections 4.3 and 4.8). In case of hypersensitivity reactions, treatment with vancomycin must be discontinued immediately and the adequate emergency measures must be initiated.In patients receiving vancomycin over a longer-term period or concurrently with other medications which may cause neutropenia or agranulocytosis, the leukocyte count should be monitored at regular intervals. All patients receiving vancomycin should have periodic haematologic studies, urine analysis, liver and renal function tests. Alvanco should be used with caution in patients with allergic reactions to teicoplanin, since cross hypersensitivity, including fatal anaphylactic shock, may occur.</p><p><u>Spectrum of antibacterial activity </u></p><p>Alvanco has a spectrum of antibacterial activity limited to Gram-positive organisms. It is not suitable for use as a single agent for the treatment of some types of infections unless the pathogen is already documented and known to be susceptible or there is a high suspicion that the most likely pathogen(s) would be suitable for treatment with vancomycin. The rational use of vancomycin should take into account the bacterial spectrum of activity, the safety profile and the suitability of standard antibacterial therapy to treat the individual patient.</p><p><u>Ototoxicity</u></p><p>Ototoxicity, which may be transitory or permanent (see section 4.8) has been reported in patients with prior deafness, who have received excessive intravenous doses, or who receive concomitant treatment with another ototoxic active substance such as an aminoglycoside. Alvanco should also be avoided in patients with previous hearing loss. Deafness may be preceded by tinnitus. Experience with other antibiotics suggests that deafness may be progressive despite cessation of treatment. To reduce the risk of ototoxicity, blood levels should be determined periodically and periodic testing of auditory function is recommended. The elderly are particularly susceptible to auditory damage. Monitoring of vestibular and auditory function in the elderly should be carried out during and after treatment. Concurrent or sequential use of other ototoxic substances should be avoided.</p><p>&nbsp;</p><p><u>Infusion-related reactions </u></p><p>Rapid bolus administration (i.e. over several minutes) may be associated with exaggerated hypotension (including shock and, rarely, cardiac arrest), histamine like responses and maculopapular or erythematous rash (&ldquo;red man&#39;s syndrome&rdquo; or &ldquo;red neck syndrome&rdquo;). Alvanco should be infused slowly in a dilute solution (2.5 to 5.0 mg/ml) at a rate no greater than 10 mg/min and over a period not less than 60 minutes to avoid rapid infusion-related reactions. Stopping the infusion usually results in a prompt cessation of these reactions. The frequency of infusion-related reactions (hypotension, flushing, erythema, urticaria and pruritus) increases with the concomitant administration of anaesthetic agents (see section 4.5). This may be reduced by administering vancomycin by infusion over at least 60 minutes, before anaesthetic induction.</p><p>&nbsp;</p><p><u>Severe bullous reactions </u></p><p>Stevens-Johnson syndrome (SJS) has been reported with the use of vancomycin (see section 4.8). If symptoms or signs of SJS (e.g. progressive skin rash often with blisters or mucosal lesions) are present, vancomycin treatment should be discontinued immediately and specialised dermatological assessment be sought.</p><p>&nbsp;</p><p><u>Administration site related reactions </u></p><p>Pain and thrombophlebitis may occur in many patients receiving intravenous vancomycin and are occasionally severe. The frequency and severity of thrombophlebitis can be minimized by administering the medicinal product slowly as a dilute solution (see section 4.2) and by changing the sites of infusion regularly. The efficacy and safety of vancomycin has not been established for the intrathecal, intralumbar and intraventricular routes of administration.</p><p>&nbsp;</p><p><u>Oral administration </u></p><p>Intravenous administration of vancomycin is not effective for the treatment of Clostridium difficile infection. Alvanco should be administered orally for this indication. Testing for Clostridium difficile colonization or toxin is not recommended in children younger than 1 year due to high rate of asymptomatic colonisation unless severe diarrhoea is present in infants with risk factors for stasis such as Hirschsprung disease, operated anal atresia or other severe motility disorders. Alternative aetiologies should always be sought and Clostridium difficile enterocolitis be proven.</p><p><u>Potential for Systemic Absorption</u></p><p>Absorption may be enhanced in patients with inflammatory disorders of the intestinal mucosa or with Clostridium difficile-induced pseudomembranous colitis. These patients may be at risk for the development of adverse reactions, especially if there is a concomitant renal impairment. The greater the renal impairment, the greater the risk of developing the adverse reactions associated with the parenteral administration of vancomycin. Monitoring of serum vancomycin concentrations of patients with inflammatory disorders of the intestinal mucosa should be performed.</p><p><u>Nephrotoxicity</u></p><p>Serial monitoring of renal function should be performed when treating patients with underlying renal dysfunction or patients receiving concomitant therapy with an aminoglycoside or other nephrotoxic drugs.</p><p><u>Ototoxicity</u></p><p>Serial tests of auditory function may be helpful in order to minimise the risk of ototoxicity in patients with an underlying hearing loss, or who are receiving concomitant therapy with an ototoxic agent such as an aminoglycoside.</p><p><u>Drug interactions with anti-motility agents and proton pump inhibitors </u></p><p>Anti-motility agents should be avoided and proton pump inhibitor use should be reconsidered.</p><p><u>Development of Drug-Resistant Bacteria</u></p><p>Oral vancomycin use increases the chance of vancomycin-resistant Enterococci populations in the gastrointestinal tract. As a consequence, prudent use of oral vancomycin is advised</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Other potentially nephrotoxic or ototoxic medications </u></p><p>Concurrent or sequential administration of vancomycin with other potentially neurotoxic or/and nephrotoxic active substances particularly gentamycin, amphotericin B, streptomycin, neomycin, kanamycin, amikacin, tobramycin, viomycin, bacitracin, polymyxin B, colistin and cisplatin may potentiate the nephrotoxicity and/or ototoxicity of vancomycin and consequently requires careful monitoring of the patient.</p><p><u>Anaesthetics</u></p><p>Concurrent administration of vancomycin and anaesthetic agents has been associated with erythema, histamine like flushing and anaphylactoid reactions. This may be reduced if the vancomycin is administered over 60 minutes before anaesthetic induction.</p><p><u>Muscle relaxants </u></p><p>If vancomycin is administered during or directly after surgery, the effect (neuromuscular blockade) of muscle relaxants (such as succinylcholine) concurrently used can be enhanced and prolonged.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>No sufficient safety experience is available regarding vancomycin during human pregnancy. Reproduction toxicological studies on animals do not suggest any effects on the development of the embryo, foetus or gestation period (see section 5.3). However, vancomycin penetrates the placenta and a potential risk of embryonal and neonatal ototoxicity and nephrotoxicity cannot be excluded. Therefore vancomycin should be given in pregnancy only if clearly needed and after a careful risk/benefit evaluation.</p><p><u>Lactation </u></p><p>Alvanco is excreted in human milk and should be therefore used in lactation period only if clearly necessary. Alvanco should be cautiously given to breast-feeding mothers because of potential adverse reactions in the infant (disturbances in the intestinal flora with diarrhoea, colonisation with yeast-like fungi and possibly sensibilisation). Considering the importance of this medicine for nursing mother, the decision to stop breastfeeding should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alvanco has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the Safety profile </u></p><p>The most common adverse reactions are phlebitis, pseudo-allergic reactions and flushing of the upper body (&ldquo;red-neck syndrome&rdquo;) in connection with too rapid intravenous infusion of vancomycin. The absorption of vancomycin from the gastrointestinal tract is negligible. However, in severe inflammation of the intestinal mucosa, especially in combination with renal insufficiency, adverse reactions that occur when vancomycin is administered parenterally may appear.</p><p><u>Tabulated List of Adverse reactions</u></p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. The adverse reactions listed below are defined using the following MedDRA convention and system organ class database:</p><p>Very common (&ge; 1/10)</p><p>common (&ge; 1/100 to &lt; 1/10)</p><p>uncommon (&ge; 1/1,000 to &lt; 1/100)</p><p>rare (&ge; 1/10,000 to &lt; 1/1,000)</p><p>very rare (&lt; 1/10,000)</p><p>not known (cannot be estimated from the available data).</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td colspan="2"><strong>System organ class</strong></td></tr><tr><td><strong>Frequency&nbsp;</strong></td><td><strong>Adverse reaction&nbsp;</strong></td></tr><tr><td colspan="2"><strong>Blood and the lymphatic system disorders:</strong></td></tr><tr><td>Rare</td><td>Reversible neutropenia<sup>1</sup>, agranulocytosis, eosinophilia, thrombocytopenia, pancytopenia</td></tr><tr><td colspan="2"><strong>Immune system disorders:</strong></td></tr><tr><td>Rare</td><td>Hypersensitivity reactions, anaphylactic&nbsp;reactions<sup>2</sup></td></tr><tr><td colspan="2"><strong>Ear and labyrinth disorders:</strong></td></tr><tr><td>Uncommon</td><td>Transient or permanent loss of hearing<sup>4</sup></td></tr><tr><td>Rare</td><td>Vertigo, tinnitus<sup>3</sup>, dizziness</td></tr><tr><td colspan="2"><strong>Cardiac disorders</strong></td></tr><tr><td>Very rare</td><td>Cardiac arrest</td></tr><tr><td colspan="2"><strong>Vascular disorders:</strong></td></tr><tr><td>Common</td><td>Decrease in blood pressure</td></tr><tr><td>Rare</td><td>Vasculitis</td></tr><tr><td colspan="2"><strong>Respiratory, thoracic and mediastinal disorders:</strong></td></tr><tr><td>Common</td><td>Dyspnoea, stridor</td></tr><tr><td colspan="2"><strong>Gastrointestinal disorders:</strong></td></tr><tr><td>Rare</td><td>Nausea</td></tr><tr><td>Very rare</td><td>Pseudomembranous enterocolitis</td></tr><tr><td>Not known</td><td>Vomiting, Diarrhoea</td></tr><tr><td colspan="2"><strong>Skin and subcutaneous tissue disorders:</strong></td></tr><tr><td>Common</td><td>Flushing of the upper body (&ldquo;red man syndrome&rdquo;), exanthema and mucosal inflammation, pruritus, urticaria</td></tr><tr><td>Very rare</td><td>Exfoliative dermatitis, Stevens-Johnson syndrome, Lyell&#39;s syndrome, Linear IgA bullous dermatosis<sup>5</sup></td></tr><tr><td>Not known</td><td>Eosinophilia and systemic symptoms (DRESS syndrome), AGEP (Acute Generalized Exanthematous Pustulosis)</td></tr><tr><td colspan="2"><strong>Renal and urinary disorders:</strong></td></tr><tr><td>Common</td><td>Renal insufficiency manifested primarily by increased serum creatinine and serum urea</td></tr><tr><td>Rare</td><td>Interstitial nephritis, acute renal failure.</td></tr><tr><td>Not known</td><td>Acute tubular necrosis</td></tr><tr><td colspan="2"><strong>General disorders and administration site conditions:</strong></td></tr><tr><td>Common</td><td>Phlebitis, redness of the upper body and face</td></tr><tr><td>Rare</td><td>Drug fever, shivering, pain and muscle spasm of the chest and back muscles</td></tr></tbody></table><p><u>Description of selected adverse drug reactions </u></p><p>Reversible neutropenia usually starting one week or more after onset of intravenous therapy or after total dose of more than 25 g. During or shortly after rapid infusion anaphylactic/ anaphylactoid reactions including wheezing may occur. The reactions abate when administration is stopped, generally between 20 minutes and 2 hours. Alvanco should be infused slowly (see sections 4.2 and 4.4). Necrosis may occur after intramuscular injection. Tinnitus, possibly preceding onset of deafness, should be regarded as an indication to discontinue treatment.</p><p>Ototoxicity has primarily been reported in patients given high doses, or in those on concomitant treatment with other ototoxic medicinal products like aminoglycosides, or in those who had a pre-existing reduction in kidney function or hearing.&nbsp;If a bullous disorder is suspected, the drug should be discontinued and specialised dermatological assessment should be carried out.</p><p>Paediatric population</p><p>The safety profile is generally consistent among children and adult patients. Nephrotoxicity has been described in children, usually in association with other nephrotoxic agents such as aminoglycosides.</p><p>&nbsp;</p><p><strong><u>Reporting of suspected adverse reactions </u></strong></p><p>Reporting suspected adverse reactions after AUTHORIZATION of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><table border="1" cellspacing="1" cellpadding="1" align="center"><tbody><tr><td><p><strong>To report any side effect(s):</strong></p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Toxicity due to overdose has been reported. 500 mg iv to a child, 2 year of age, resulted in lethal intoxication.</p><p>Administration of a total of 56 g during 10 days to an adult resulted in renal insufficiency. In certain high-risk conditions (e. g. in case of severe renal impairment) high serum levels and oto- and nephrotoxic effects can occur.</p><p>Measures in case of overdose:</p><p>&bull; A specific antidote is not known.</p><p>&bull; Symptomatic treatment while maintaining renal function is required Vancomycin is poorly removed from the blood by haemodialysis or peritoneal dialysis. Haemofiltration or haemoperfusion with polysulfone resins have been used to reduce serum concentrations of vancomycin.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: 1.1.11 Anti-infectives. Antibacterials. Other antibacterials. ATC Code: J01XA01 &ndash; Anti-infectives for systemic use &ndash; Antibacterials for systemic use &ndash; Other antibacterials &ndash; Glycopeptide antibacterials.</p><p><u>Mechanism of action </u></p><p>Vancomycin is a tricyclic glycopeptide antibiotic that inhibits the synthesis of the cell wall in sensitive bacteria by binding with high affinity to the D-alanyl-D-alanine terminus of cell wall precursor units. The drug is slowly bactericidal for dividing microorganisms. In addition, it impairs the permeability of the bacterial cell membrane and RNA synthesis.</p><p><u>Pharmacokinetic/ Pharmacodynamic relationship </u></p><p>Vancomycin displays concentration-independent activity with the area under the concentration curve (AUC) divided by the minimum inhibitory concentration (MIC) of the target organism as the primary predictive parameter for efficacy. On basis of in vitro, animal and limited human data, an AUC/MIC ratio of 400 has been established as a PK/PD target to achieve clinical effectiveness with vancomycin. To achieve this target when MICs are &ge; 1.0 mg/l, dosing in the upper range and high trough serum concentrations (15-20 mg/l) are required (see section 4.2).</p><p>&nbsp;</p><p><u>Mechanism of resistance </u></p><p>Acquired resistance to glycopeptides is most common in enterococci and is based on acquisition of various van gene complexes which modifies the D-alanyl-D-alanine target to D-alanyl-D-lactate or Dalanyl-D-serine which bind vancomycin poorly. In some countries, increasing cases of resistance are observed particularly in enterococci; multi-resistant strains of Enterococcus faecium are especially alarming.</p><p>Van genes have rarely been found in Staphylococcus aureus, where changes in cell wall structure result in &ldquo;intermediate&rdquo; susceptibility, which is most commonly heterogeneous. Also, methicillin-resistant staphylococcus strains (MRSA) with reduced susceptibility for vancomycin were reported. The reduced susceptibility or resistance to vancomycin in Staphylococcus is not well understood. Several genetic elements and multiple mutations are required. There is no cross-resistance between vancomycin and other classes of antibiotics. Cross-resistance with other glycopeptide antibiotics, such as teicoplanin, does occur. Secondary development of resistance during therapy is rare.</p><p><u>Synergism </u></p><p>The combination of vancomycin with an aminoglycoside antibiotic has a synergistic effect against many strains of Staphylococcus aureus, non-enterococcal group D-streptococci, enterococci and streptococci of the Viridans group. The combination of vancomycin with a cephalosporin has a synergistic effect against some oxacillin-resistant Staphylococcus epidermidis strains, and the combination of vancomycin with rifampicin has a synergistic effect against Staphylococcus epidermidis and a partial synergistic effect against some Staphylococcus aureus strains. As vancomycin in combination with a cephalosporin may also have an antagonistic effect against some Staphylococcus epidermidis strains and in combination with rifampicin against some Staphylococcus aureus strains, preceding synergism testing is useful. Specimens for bacterial cultures should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to vancomycin.</p><p><u>Susceptibility testing breakpoints </u></p><p>Vancomycin is active against gram-positive bacteria, such as staphylococci, streptococci, enterococci, pneumococci, and clostridia. Gram-negative bacteria are resistant.&nbsp;The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable. This information only provides approximate guidance on the chance whether micro-organisms are susceptible to vancomycin.</p><p>Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>&nbsp;</td><td>Susceptible</td><td>Resistant</td></tr><tr><td>Staphylococcus aureus<sup>1</sup></td><td>&le; 2 mg/L</td><td>&gt; 2 mg/L</td></tr><tr><td>Coagulase-negative staphylococci<sup>1</sup></td><td>&le; 4 mg/L</td><td>&gt; 4 mg/L</td></tr><tr><td>Enterococcus spp.</td><td>&le; 4 mg/L</td><td>&gt; 4 mg/L</td></tr><tr><td>Streptococcus groups A, B, C and G</td><td>&le; 2 mg/L</td><td>&gt; 2 mg/L</td></tr><tr><td>Streptococcus pneumoniae</td><td>&le; 2 mg/L</td><td>&gt; 2 mg/L</td></tr><tr><td>Gram positive anaerobes</td><td>&le; 2 mg/L</td><td>&gt; 2 mg/L</td></tr></tbody></table><p><sup>1</sup> S. aureus with vancomycin MIC values of 2 mg/L are on the border of the wild type distribution and there may be an impaired clinical response.</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><u><strong>Commonly susceptible species</strong></u></td></tr><tr><td><p><strong>Gram positive </strong></p><p>Enterococcus faecalis</p><p>Staphylococcus aureus</p><p>Methicillin-resistant Staphylococcus aureus coagulase-negative Staphylococci</p><p>Streptococcus spp.</p><p>Streptococcus pneumoniae</p><p>Enteroccocus spp.</p><p>Staphylococcus spp.</p><p><strong>Anaerobic species </strong></p><p>Clostridium spp. except Clostridium</p><p>innocuum</p><p>Eubacterium spp.</p><p>Peptostreptococcus spp.</p></td></tr><tr><td><strong>Species for which acquired resistance may be a problem</strong></td></tr><tr><td>Enterococcus faecium</td></tr><tr><td><strong>Inherently resistant</strong></td></tr><tr><td><p><strong>All Gram negative bacteria</strong></p><p><strong>Gram positive aerobic specie</strong>s</p><p>Erysipelothrix rhusiopathiae,</p><p>Heterofermentative Lactobacillus,</p><p>Leuconostoc spp</p><p>Pediococcus spp.</p><p><strong>Anaerobic species</strong></p><p>Clostridium innocuum</p></td></tr><tr><td>The emergence of resistance towards vancomycin differs from one hospital to another and a local microbiological laboratory should therefore be contacted for relevant local information.</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Vancomycin is administered intravenously for the treatment of systemic infections. In the case of patients with normal renal function, intravenous infusion of multiple doses of 1g vancomycin (15 mg/kg) for 60 minutes produces approximate average plasma concentrations of 50-60 mg/L, 20-25 mg/L and 5-10 mg/L, immediately, 2 hours and 11 hours after completing the infusion, respectively. The plasma levels obtained after multiple doses are similar to those achieved after a single dose. Vancomycin is not usually absorbed into the blood after oral administration. However, absorption may occur after oral administration in patients with (pseudomembranous) colitis. This may lead to vancomycin accumulation in patients with co-existing renal impairment.</p><p><u>Distribution </u></p><p>The volume of distribution is about 60 L/1.73 m2 body surface. At serum concentrations of vancomycin of 10 mg/l to 100 mg/l, the binding of the drug to plasma proteins is approximately 30-55%, measured by ultra-filtration. Vancomycin diffuses readily across the placenta and is distributed into cord blood. In non-inflamed meninges, vancomycin passes the blood-brain barrier only to a low extent.</p><p><u>Biotransformation </u></p><p>There is very little metabolism of the drug. After parenteral administration it is excreted almost completely as microbiologically active substance (approx. 75-90% within 24 hours) through glomerular filtration via the kidneys.</p><p><u>Elimination </u></p><p>The elimination half-life of vancomycin is 4 to 6 hours in patients with normal renal function and 2.2-3 hours in children. Plasma clearance is about 0.058 L/kg/h and kidney clearance about 0.048 L/kg/h. In the first 24 hours, approximately 80 % of an administered dose of vancomycin is excreted in the urine through glomerular filtration. Renal dysfunction delays the excretion of vancomycin. In anephric patients, the mean half-life is 7.5 days. Due to ototoxicity of vancomycin therapy-adjuvant monitoring of the plasma concentrations is indicated in such cases. Biliary excretion is insignificant (less than 5% of a dose). Although the vancomycin is not eliminated efficiently by haemodialysis or peritoneal dialysis, there have been reports of an increase in vancomycin clearance with haemoperfusion and haemofiltration. After oral administration, only a fraction of the administered dose is recovered in the urine. In contrast, high concentrations of vancomycin are found in the faeces (&gt;3100 mg/kg with doses of 2 g/day).</p><p><u>Linerarity/non-linearity</u></p><p>Vancomycin concentration generally increases proportionally with increasing dose. Plasma concentrations during multiple dose administration are similar to those after the administration of a single dose.</p><p><u>Characteristics in specific groups </u></p><p><em>Renal impairment </em></p><p>Vancomycin is primarily cleared by glomerular filtration. In patients with impaired renal function the terminal elimination half- life of vancomycin is prolonged and the total body clearance is reduced. Subsequently, optimal dose should be calculated in line with dosing recommendations provided in section 4.2.</p><p><em>Hepatic impairment</em></p><p>Vancomycin pharmacokinetics is not altered in patients with hepatic impairment. Pregnant Women: Significantly increased doses may be required to achieve therapeutic serum concentrations in pregnant women (see Section 4.6).</p><p><em>Overweight patients</em></p><p>Vancomycin distribution may be altered in overweight patients due to increases in volume of distribution, in renal clearance and possible changes in plasma protein binding. In these subpopulations vancomycin serum concentration were found higher than expected in male healthy adults (see section 4.2).</p><p>&nbsp;</p><p><u>Paediatric population </u></p><p>Vancomycin PK has shown wide inter-individual variability in preterm and term neonates. In neonates, after intravenous administration, vancomycin volume of distribution varies between 0.38 and 0.97 L/kg, similar to adult values, while clearance varies between 0.63 and 1.4 ml/kg/min. Half-life varies between 3.5 and 10 h and is longer than in adults, reflecting the usual lower values for clearance in the neonate. In infants and older children, the volume of distribution ranges between 0.26-1.05 L/kg while clearance varies between 0.33-1.87 ml/kg/min.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No reproduction tests were performed with the drug, so its effect on reproduction is not known. A conventional teratology study performed in female rats revealed no teratogenic effects and the same occurred in a similar study in female rabbits. In these species, the target organ of toxicity was the kidney. Vancomycin has been studied in a number of standard studies in vitro and in vivo to determine the mutagenic potential, involving scanning of non-specific DNA damage, incidental mutations, chromosomal damage and loss of chromosomes. The medicinal product was not genotoxic.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium hydroxide and hydrochloric acid (for pH adjustment).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alvanco solutions have a low pH that may cause chemical or physical instability if mixed with other compounds. Mixing with alkaline solutions should be avoided. Therefore, each parental solution should be checked visually for precipitation and discolouration prior to use. This medicinal product must not be mixed with other solutions for infusion except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder:
2 years
Reconstituted Solution:
For intravenous use, the reconstituted solution should be diluted immediately after preparation. 
For oral use, the reconstituted solution with purified water for oral administration is stable when 
stored at 2-8 °C for 48 hours

Diluted solution:
Chemical and physical in- use stability has been demonstrated:
• for a period of 24 hours at 25 °C, after reconstitution and further dilution with sodium 
chloride 9 mg/ml (0.9%) or glucose solution 50 mg/ml (5%);
• for a period of 96 hours when stored at 2-8 °C, after reconstitution and further dilution with 
sodium chloride 9 mg/ml (0.9%) or glucose solution 50 mg/ml (5%), or Ringer's lactate 
solution or with sodium chloride 9 mg/ml (0.9%) + glucose 50 mg/ml (5%).
From a microbiological point of view the medicinal product should be used immediately.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Powder as packed for sale</p><p>Do not store above 30 &deg;C.</p><p>Keep the vial in the outer carton in order to protect from light</p><p>For storage conditions of the reconstituted medicinal product and diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immediate packaging: colourless type I glass vial, with a rubber stopper and a white aluminium flip-off cap.</p><p>Secondary packaging: cartons containing 1, 5, 10 or 20 vials.</p><p>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reconstituted solutions containing 50 mg/ml of vancomycin should be further diluted depending on the method of administration.</p><p><u><strong>Preparation of the reconstituted solution</strong></u></p><p>Dissolve the powder in 10 ml of sterile Water for injection</p><p>One ml of reconstituted solution contains 50 mg of vancomycin.</p><p><strong><u>Appearance of reconstituted solution</u></strong></p><p>After reconstitution the solution is clear and colorless to slightly yellowish brown without visible particles.</p><p>For storage conditions of the reconstituted medicinal product, see section 6.3</p><p><strong><u>Preparation of final diluted Solution for infusion </u></strong></p><p>Reconstituted solutions containing 50 mg/ml of vancomycin should be further diluted.</p><p>Suitable diluents are:</p><p>&bull; 5% Glucose Injection</p><p>&bull; 0.9% Sodium Chloride Injection</p><p>&bull; 5% Glucose Injection with 0.9% Sodium Chloride Injection</p><p>&bull; Ringer&#39;s Lactate Injection</p><p><strong>Intermittent infusion: </strong></p><p>Reconstituted solution containing 500 mg vancomycin (50 mg/ml) must be diluted further with at least 100 ml diluent (to 5 mg/ml) The concentration of vancomycin in Solution for infusion should not exceed 5 mg/ml. The desired dose should be administered slowly by intravenous use at a rate of no more than 10 mg/minute, for at least 60 minutes or even longer.</p><p><strong>Continuous infusion:</strong></p><p>This should be used only if treatment with an intermittent infusion is not possible. Dilute 1000 mg to 2000 mg of dissolved vancomycin in a sufficient amount of the above suitable diluent and administer it in the form of a drip infusion, so that the patient will receive the prescribed daily dose in 24 hours.</p><p><strong>Oral Administration</strong></p><p>The contents of vials for parenteral administration may be used. The reconstituted solutions containing 500 mg and 1000 mg of vancomycin can be diluted in 30 ml of water and given to the patient or administered through a nasogastric tube.</p><p><u>Appearance of diluted solution </u></p><p>After dilution the solution is clear and colorless without visible particles. For storage conditions of the diluted medicinal product, see section 6.3. Before administration, the reconstituted and diluted solutions should be inspected visually for particulate matter and discoloration. Only clear, and colorless solution free from particles should be used.</p><p><strong>Disposal</strong></p><p>Vials are for single use only. Unused medicinal products must be discarded. Any unused medicinal product or waste material should be disposed of in accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:
Sofarimex – Indústria Química e Farmacêutica, S.A.
Av. das Indústria, Alto de Colaride
2735-213 Cacém
Portugal
For:
SPIMACO
Al-Qassim pharmaceutical plant
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>